Celgene's Positive Ozanimod Data Puts Focus On MS Commercialization

A second Phase III multiple sclerosis trial testing the S1P1 modulator was positive, turning attention to whether or not Celgene will market the drug independently for the indication and how the drug might be positioned against an eventual generic Gilenya.

Multiple Sclerosis

Positive data from a second Phase III trial testing Celgene Corp.'s ozanimod in multiple sclerosis has positioned the drug for a US FDA regulatory filing by the end of the year, raising new questions about the commercial strategy in MS and forthcoming generics for an established drug.

The company announced on May 22 that it had the data it needed to turn its attention to a new...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from R&D

MBX Surges As Phase II Data Show Competitive Profile For Canvuparatide

 
• By 

MBX Biosciences reported Phase II results for once-weekly canvuparatide that showed comparable efficacy to Ascendis Pharma’s once-daily Yorvipath for hypoparathyroidism.

Ionis Targets Ultra-Rare Disease Market With Zilganersen

 

The biotech announced positive topline results from its pivotal study in Alexander disease, which has an estimated population of about 300 in the US.

Stealth Bio Bags Elamipretide FDA Win After Multiple Setbacks

 

Stealth won FDA accelerated approval for Forzinity, the first Barth syndrome therapy, after multiple regulatory setbacks. The decision sets the stage for confirmatory trials and expanded patient access.

EADV: UCB’s Bimzelx Primed To Maintain Pole Position in HS

 
• By 

The Belgium-based group has collected heaps of long-term efficacy and safety data which will help stave off the competition.

More from Scrip

EADV: UCB’s Bimzelx Primed To Maintain Pole Position in HS

 
• By 

The Belgium-based group has collected heaps of long-term efficacy and safety data which will help stave off the competition.

Roche’s evERA Giredestrant Study Hits In All-Comer Breast Cancer Population

 

The Phase III trial of the SERD has shown a significant benefit in the intent-to-treat and ESR1-mutated populations in post-CDK ER+/HER2- metastatic breast cancer but whether the data will be enough to support an equally broad approval remains to be seen.

Pipeline Watch: Six Approvals And Twenty Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.